title: Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan.
abstract: OBJECTIVE
  To evaluate treatment satisfaction, efficacy and functional ability of the rapid release formulation of sumatriptan 100 mg tablets (sumatriptan RT 100 mg) in an early intervention paradigm in patients who were dissatisfied with low-dose sumatriptan and not completely satisfied with their current migraine regimen.
  
  
  METHODS
  Experienced migraineurs who reported a mild migraine pain phase, dissatisfaction with the previous sumatriptan treatment and some dissatisfaction with their current treatment regimen had no experience with sumatriptan at the 100 mg dose were enrolled in an open-label, single group study. Subjects were instructed to treat four migraine attacks within 30 min of the onset of mild pain. Treatment satisfaction was measured with the Patient Perception of Migraine Questionnaire Revised version (PPMQ-R) questionnaire.
  
  
  RESULTS
  More than half of the subjects were either very satisfied or satisfied with the efficacy of early intervention sumatriptan RT 100 mg after each attack and at the follow-up study visit. The mean total PPMQ-R score was 75.2 out of 100. Between 63% and 73% of subjects were pain-free within 4 h of dosing. Between 79% and 90% of subjects reported an ability to function normally within 4 h of taking the study medication.
  
  
  CONCLUSIONS
  Subjects who were previously unsatisfied with lower doses of sumatriptan and less than very satisfied with their current treatment regimen were more likely to be satisfied or very satisfied with sumatriptan RT 100 mg in an early intervention paradigm. Results were consistent across four migraine attacks and at a follow-up visit. The treatment satisfaction results corresponded with positive results on efficacy measures and a functional status measure.
authors.affiliation: The Headache Institute, Roosevelt Hospital Center, New York, Albert Einstein College of Medicine Bronx, NY 10019, USA. lnewman@chpnet.org
authors.forename: L C
authors.initials: LC
authors.lastname: Newman
authors.forename: R K
authors.initials: RK
authors.lastname: Cady
authors.forename: S
authors.initials: S
authors.lastname: Landy
authors.forename: P
authors.initials: P
authors.lastname: O'Carroll
authors.forename: W J
authors.initials: WJ
authors.lastname: Kwong
authors.forename: S P
authors.initials: SP
authors.lastname: Burch
authors.forename: A C
authors.initials: AC
authors.lastname: Nelsen
authors.forename: S A
authors.initials: SA
authors.lastname: McDonald
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D017060:Patient Satisfaction; D011446:Prospective Studies; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*; D018170:Sumatriptan / Q000008:administration & dosage*; D013607:Tablets; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D017366:Serotonin Receptor Agonists; D013607:Tablets; D018170:Sumatriptan